Tikvah Management’s Standard BioTools LAB Stock Holding History

Tikvah Management’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.92M	Sell	3,551,058 -94	-0%	-$89	0.89%	14
2026 Q1	$3.26M	Hold	3,551,152	–	–	1.01%	16
2025 Q4	$4.55M	Hold	3,551,152	–	–	1.21%	17
2025 Q3	$4.62M	Sell	3,551,152 -1,499,906	-30%	-$1.96M	1.36%	18
2025 Q2	$6.06M	Sell	5,051,058 -1,500,000	-23%	-$1.66M	1.95%	15
2025 Q1	$7.08M	Hold	6,551,058	–	–	2.41%	14
2024 Q4	$11.5M	Hold	6,551,058	–	–	3.12%	10
2024 Q3	$12.6M	Hold	6,551,058	–	–	3.92%	9
2024 Q2	$11.6M	Hold	6,551,058	–	–	3.78%	9
2024 Q1	$17.8M	Buy	+6,551,058	New	+$15.8M	5.56%	6
2022 Q1	–	Sell	-1,250,000	Closed	-$4.9M	–	25
2021 Q4	$4.9M	Hold	1,250,000	–	–	1.37%	15
2021 Q3	$8.24M	Hold	1,250,000	–	–	2.23%	12
2021 Q2	$7.7M	Hold	1,250,000	–	–	2.13%	11
2021 Q1	$5.65M	Hold	1,250,000	–	–	1.58%	11
2020 Q4	$7.5M	Hold	1,250,000	–	–	2.09%	11
2020 Q3	$9.29M	Hold	1,250,000	–	–	2.87%	10
2020 Q2	$5.01M	Buy	+1,250,000	New	+$4.35M	1.53%	15

Other funds holding LAB

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Tikvah Management's LAB Position: Q2 2026 in Review

Tikvah Management reduced its Standard BioTools (LAB) stake by 0% in Q2 2026, selling an estimated $89 and leaving 3,551,058 shares worth $2.92M. The position accounts for 0.89% of the portfolio, ranked #14.

Tikvah Management first reported a position in LAB in Q2 2020 and has held it in 17 quarters since. The position peaked at $17.8M in Q1 2024. 144 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

Tikvah Management held 3,551,058 shares of Standard BioTools worth $2.92M as of Q2 2026.
Tikvah Management sold 94 Standard BioTools shares in Q2 2026, an estimated $89.
Standard BioTools made up 0.89% of Tikvah Management's portfolio in Q2 2026, its #14 holding.
Tikvah Management first reported a position in Standard BioTools in Q2 2020 and has held it in 17 quarters since.
Tikvah Management's Standard BioTools position peaked at $17.8M in Q1 2024.
144 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Tikvah Management's 13F filing for Q2 2026, filed 13 Aug 2026.